Analysis of treatment results in advanced Hodgkin's disease: The case for adjuvant radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 56, Issue 3, 2003, Pages 634-643

  Dyduch, Magdalena ^a   Skolyszewski, Jan ^a   Korzeniowski, Stanislaw ^a   Sokolowski, Andrzej ^b  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b CRACOW UNIVERSITY OF ECONOMICS   (Poland)

Author keywords

Advanced Hodgkin's disease; Consolidation radiotherapy

Indexed keywords

CHEMOTHERAPY; DISEASE CONTROL; IRRADIATION;

THERAPEUTIC PROGNOSTIC FACTORS;

RADIOTHERAPY;

BLEOMYCIN; CHLORMETHINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; SERUM ALBUMIN; VINCRISTINE;

ADJUVANT THERAPY; ADULT; AGE; ARTICLE; CANCER CHEMOTHERAPY; FEMALE; HODGKIN DISEASE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0038620373     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00129-9     Document Type: Article

References (44)

1. DeVita V.T., Serpick A.A., Carbone P.P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 73:1970;881-895.
2. Bonadonna G., Zucali R., Monfardini S., et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 36:1975;252-259.
3. Bonadonna G., Santoro A. ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev. 9:1982;21-35.
4. Santoro A., Bonadonna G., Valagussa P., et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy . J Clin Oncol. 5:1987;27-37.
5. Bonadonna G., Valagussa P., Santoro A., et al. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease A report of 8-year results . Ann Intern Med. 104:1986;739-746.
6. Canellos G.P., Anderson J.R., Propert K.J., et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 327:1992;1478-1484.
7. Somers R., Carde P., Henry-Amar M., et al. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD A European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial . J Clin Oncol. 12:1994;279-287.
8. Wu J.J., Prosnitz L.R. The role of adjuvant radiation therapy for stages III and IV Hodgkin's disease. Semin Radiat Oncol. 6:1996;196-209.
9. Horning S.J., Williams J., Bartlett N.L., et al. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease Eastern Cooperative Oncology Group pilot study E1492 . J Clin Oncol. 18:2000;972-980.
10. Diehl V., Franklin J., Hasenclever D., et al. BEACOPP, a new dose-escalated, and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma Interim report from a trial of the German Hodgkin's Lymphoma Study Group . J Clin Oncol. 16:1998;3810-3821.
11. Gustafsson A, ed. Hodgkin's disease. In: Radiotherapy for cancer. Vol. 2. A critical review of literature. Acta Oncol 1996;(Suppl. 7):93-102.
12. Straus D.J. Treatment of Hodgkin's disease The role of radio- and/or chemotherapy in advanced stages . Baillieres Clin Haematol. 9:1996;553-558.
13. Raemaekers J., Burgers M., Henry-Amar M., et al. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy Interim results from the ongoing EORTC-LCG and GPMC phase III trial . Ann Oncol. 8:(Suppl. 1):1997;111-114.
14. Frei E., Luce J., Gamble J.F., et al. Combination chemotherapy in advanced Hodgkin's disease Induction and maintenance of remission . Ann Intern Med. 79:1973;376-382.
15. Young R.C., Canellos G.P., Chabner B.A., et al. Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer. 42:1978;1001-1007.
16. Brizel D.M., Winer E.P., Prosnitz L.R., et al. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. Int J Radiat Oncol Biol Phys. 19:1990;535-542.
17. Hoppe R.T. Hodgkin's disease - The role of radiation therapy in advanced disease. Ann Oncol. 7:(Suppl. 4):1996;99-103.
18. Horning S.J., Ang P.T., Hoppe R.T., et al. The Stanford experience with combined procarbazine, Alkeran and vinblastine (PAVe) and radiotherapy for locally extensive and advanced stage Hodgkin's disease. Ann Oncol. 3:1992;747-754.
19. Prosnitz L.R., Farber L.R., Kapp D.S., et al. Combined modality therapy for advanced Hodgkin's disease 15-year follow-up data . J Clin Oncol. 6:1988;603-612.
20. Yahalom J., Ryu J., Straus D.J., et al. Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations. J Clin Oncol. 9:1991;2193-2201.
21. Fabian C.J., Mansfield C.M., Dahlberg S., et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin's disease A Southwest Oncology Group randomized study . Ann Intern Med. 120:1994;903-912.
22. Longo DL, ed. Advanced Hodgkin's disease. Are we making any progress? Clin Oncol Alert. 14:1999;81-83.
23. Viviani S., Bonfante V., Santoro A., et al. Long-term results of an intensive regimen VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease . Cancer J Sci Am. 5:1999;275-282. [Abstract].
24. Carde P. Who are the high-risk patients with Hodgkin's disease? Leukemia. 10:(Suppl. 2):1996;62-67.
25. Ferme C., Bastion Y., Brice P., et al. Prognosis of patients with advanced Hodgkin's disease Evaluation of four prognostic models using 344 patients included in the Group d'Etudes des Lymphomes de l'Adulte Study . Cancer. 80:1997;1124-1133.
26. Lee S.M., Radford J.A., Ryder W.D.J., et al. Prognostic factors for disease progression in advanced Hodgkin's disease An analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapy . Br J Cancer. 75:1997;110-115.
27. Specht L. Prognostic factors in Hodgkin's disease. Semin Radiat Oncol. 6:1996;146-161.
28. Wagstaff J., Gregory W.M., Swindek R., et al. Prognostic factors for survival in stage III B and IV Hodgkin's disease A multivariate analysis comparing two specialist treatment centres . Br J Cancer. 58:1988;487-492.
29. Hasenclever D, Diehl V, for the International Prognostic Factors Project on Advanced Hodgkin's Disease. A prognostic score for advanced Hodgkin's disease. N Engl J Med1998;339:1506-1514.
30. Klimo P., Connors J.M. MOPP/ABV hybrid program Combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease . J Clin Oncol. 3:1985;1174-1182.
31. Andrieu J.M., Jais J.P., Colonna P., et al. Ten-year results of a strategy combining three cycles of ABVD and high-dose extended irradiation for treating Hodgkin's disease at advanced stages. Ann Oncol. 9:1998;195-203.
32. Hancock B.W., Vaughan Hudson G., Vaughan Hudson B., et al. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease - Long term results. Br J Cancer. 63:1991;579-582.
33. Yelle L., Bergsagel D., Basco V., et al. Combined modality therapy of Hodgkin's disease 10-year results of National Cancer Institute of Canada Clinical Trials Group multicenter clinical trial . J Clin Oncol. 9:1991;1983-1993.
34. Coleman M., Rafla S., Propert K.J., et al. Augmented therapy of extensive Hodgkin's disease Radiation to known disease or prolongation of induction chemotherapy did not improve survival - Results of a Cancer and Leukemia Group B study . Int J Radiat Oncol Biol Phys. 41:1998;639-645.
35. Gobbi P.G., Pieresca C., Ghiradelli M.L., et al. Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease. Blood. 91:1998;2704-2712.
36. Montoto S., Camos M., Lopez-Guillermo A., et al. Hybrid chemotherapy of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin's disease. Cancer. 88:2000;2142-2148.
37. Young C.W., Straus D.J., Myers J., et al. Multidisciplinary treatment of advanced Hodgkin's disease by an alternating chemotherapeutic regimen of MOPP/ABVD and low-dose radiation therapy restricted to originally bulky disease. Cancer Treat Rep. 66:1982;907-914.
38. Cullen M.K., Stuart N.S., Woodroffe C., et al. ChlVPP/PaBlOE and radiotherapy in advanced Hodgkin's disease. J Clin Oncol. 12:1994;779-787.
39. Radkowski A., Dyduch M., Korzeniowski S., Skołyszewski J. Assessment of treatment results in patients with stage IIIB and IV Hodgkin's disease. Nowotwory. 49:1998;416-424.
40. Rosenberg S.A., Kaplan H.S. The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease 1962-1984 . Int J Radiat Oncol Biol Phys. 11:1985;5-22.
41. Pavlovsky S., Santarelli M.T., Sackmann M.F., et al. Randomized trial of chemotherapy plus radiotherapy for stage III-IV A and B Hodgkin's disease. Ann Oncol. 3:1992;533-537.
42. Ferme C., Sebban C., Hennequin C., et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 trial . Blood. 95:2000;2246-2252.
43. Bonfante V., Santoro A., Viviani S., et al. ABVD in the treatment of Hodgkin's disease. Semin Oncol. 19:(Suppl. 5):1992;38-45.
44. Straus D.J., Myers J., Lee B.J., et al. Treatment of advanced Hodgkin's disease with chemotherapy and irradiation. Am J Med. 76:1984;270-278.